Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pebble Global Holdings currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution landscape is narrow, with 1 distinct examiner and 1 distinct art unit involved. This suggests that the company's active patent matters are being handled by a single administrative unit at the patent office. For a biotechnology firm, this concentration can be beneficial for ensuring that the technical descriptions of biological inventions are interpreted consistently by the same examiner throughout the prosecution process.
ROBERT FRANKLIN SPAINE is the busiest examiner for the portfolio, overseeing 1 busiest examiner pending office action. This single action accounts for the total of 1 pending office action for the company. The use of 1 distinct examiner and 1 distinct art unit indicates a focused prosecution strategy for the current biotechnology filings. This allows the practitioner to focus their efforts on the specific requirements and examination style of this one examiner. By concentrating on a single point of review, the company can more effectively manage its resources and work toward a resolution of the pending office action in a more streamlined manner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681009 | NON-PSYCHOACTIVE MULTI-CANNABINOID AND TERPENE-BASED THERAPEUTIC COMPOSITIONS AND METHODS OF THEIR ADMINISTRATION | SPAINE, ROBERT FRANKLIN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681009 | NON-PSYCHOACTIVE MULTI-CANNABINOID AND TERPENE-BASED THERAPEUTIC COMPOSITIONS AND METHODS OF THEIR ADMINISTRATION | SPAINE, ROBERT FRANKLIN | 1655 | §101§103Other | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPebble Global Holdings has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert Franklin Spaine has the most, with 1 of Pebble Global Holdings's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
